Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04313075

A Compassionate Use Study of Leronlimab in Breast Cancer

Metastatic Triple-Negative Breast Carcinoma Clinical Trial

Official title:
A Compassionate Use Study of Leronlimab (PRO 140) in Combination With Treatment of Physician's Choice in Patients With CCR5+ Metastatic Triple Negative Breast Cancer (mTNBC)

Clinical Trial Summary

This is a single arm, compassionate use study with 30 patients for leronlimab (PRO 140) combined with a treatment of physician's choice (TPC) in patients with CCR5+ mTNBC.

Clinical Trial Description

This is a single arm, compassionate use study with 30 patients for leronlimab (PRO 140) combined with a treatment of physician's choice (TPC) in patients with CCR5+ mTNBC. Leronlimab (PRO 140) will be administered subcutaneously as weekly dose of 350 mg until disease progression or intolerable toxicity. Treatment of Physician's Choice (TPC) is defined as one of the following single-agent chemotherapy drugs administrated according to local practice: eribulin, gemcitabine, capecitabine, paclitaxel, nab-paclitaxel, vinorelbine, ixabepilone, or carboplatin. The selected treatment should be administered as per the dosing schedule included on the package insert. In this study, patients will be evaluated for tumor response approximately every 3 months or according to institution's standard practice by CT, PET/CT or MRI with contrast (per treating investigator's discretion) using the same method as at baseline. Tumor measurements will be done using RECIST v1.1. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04313075
Study type Expanded Access
Source CytoDyn, Inc.
Contact
Status No longer available
Phase
View Details
See also
  Status Clinical Trial Phase
Completed NCT03106415 - Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer Phase 1/Phase 2
Suspended NCT05673200 - Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer Phase 1
Active, not recruiting NCT02595905 - Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases Phase 2
Suspended NCT05770531 - Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy Phase 2
Active, not recruiting NCT05081492 - CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer Phase 1
Recruiting NCT05318469 - Ivermectin and Balstilimab for the Treatment of Metastatic Triple Negative Breast Cancer Phase 1/Phase 2
Not yet recruiting NCT05539365 - Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer Phase 2
Recruiting NCT04664829 - The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC Phase 1
Active, not recruiting NCT04514484 - Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Phase 1
Not yet recruiting NCT06008275 - Neratinib in Combination With Ruxolitinib in Patients With mTNBC Early Phase 1
Withdrawn NCT05093387 - SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast Cancer Phase 1
Terminated NCT03579472 - M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer Phase 1
Completed NCT02898207 - Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer Phase 1
Suspended NCT05422794 - Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer Phase 1
Completed NCT03853707 - Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer Phase 1/Phase 2
Recruiting NCT05269381 - Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors Phase 1/Phase 2
Terminated NCT02706392 - Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies Phase 1
Active, not recruiting NCT04345913 - Testing the Addition of Copanlisib to Eribulin for the Treatment of Advanced-Stage Triple Negative Breast Cancer Phase 1/Phase 2
Not yet recruiting NCT06434064 - Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer Phase 2
Not yet recruiting NCT06324240 - Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer Phase 1